Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5561034 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBCYP1A2ALDH1A1LMNA | |
| SCHEMBL5566177 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBCYP1A2ALDH1A1LMNA | |
| SCHEMBL5561505 | 0.79 | HTT (0.46) | SMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL4480477 | 0.79 | ESR1 (0.48) | SMN1; SMN2CYP1A2ALDH1A1LMNAKDM4E | |
| SCHEMBL5564914 | 0.78 | HSD17B10 (0.44) | SMN1; SMN2POLBCYP1A2ALDH1A1LMNA | |
| SCHEMBL2074934 | 0.78 | HSD17B10 (0.44) | SMN1; SMN2POLBCYP1A2ALDH1A1LMNA | |
| SCHEMBL834442 | 0.78 | HSD17B10 (0.44) | SMN1; SMN2POLBCYP1A2ALDH1A1LMNA | |
| SCHEMBL6696454 | 0.75 | GAA (0.48) | ALDH1A1 | |
| SCHEMBL5565752 | 0.73 | MAPT (0.45) | CYP1A2ALDH1A1KDM4E | |
| SCHEMBL5566470 | 0.73 | MAPT (0.45) | CYP1A2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | EXITHERA PHARMACEUTICALS LLC | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | SERPINC1, F11, F13B | SMN1; SMN2 4725/4885POLB 4601/4885CYP1A2 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.